These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36822966)

  • 1. Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model.
    Sabato B; Augusto PSA; Lima Gonçalves Pereira R; Coutinho Batista Esteves F; Caligiorne SM; Rodrigues Dias Assis B; Apolo Correia Marcelino S; Pires do Espírito Santo L; Dias Dos Reis K; Da Silva Neto L; Goulart G; de Fátima Â; Pierezan F; Toshio Fujiwara R; Castro M; Garcia F
    Vaccine; 2023 Mar; 41(13):2127-2136. PubMed ID: 36822966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calix[
    da Silva Neto L; da Silva Maia AF; Godin AM; de Almeida Augusto PS; Pereira RLG; Caligiorne SM; Alves RB; Fernandes SOA; Cardoso VN; Goulart GAC; Martins FT; das Neves MCL; Garcia FD; de Fátima Â
    J Adv Res; 2022 May; 38():285-298. PubMed ID: 35572397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future potential for cocaine vaccines.
    Orson FM; Wang R; Brimijoin S; Kinsey BM; Singh RA; Ramakrishnan M; Wang HY; Kosten TR
    Expert Opin Biol Ther; 2014 Sep; 14(9):1271-83. PubMed ID: 24835496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccine.
    Hicks MJ; Kaminsky SM; De BP; Rosenberg JB; Evans SM; Foltin RW; Andrenyak DM; Moody DE; Koob GF; Janda KD; Ricart Arbona RJ; Lepherd ML; Crystal RG
    Hum Gene Ther Clin Dev; 2014 Mar; 25(1):40-9. PubMed ID: 24649839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the feasibility of an anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies.
    Schabacker DS; Kirschbaum KS; Segre M
    Immunology; 2000 May; 100(1):48-56. PubMed ID: 10809958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: A phase 1 clinical trial.
    Watanabe A; Nishida S; Burcu T; Shibahara T; Kusakabe T; Kuroda E; Ishii KJ; Kumanogoh A
    Vaccine; 2022 Jul; 40(31):4150-4159. PubMed ID: 35672178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
    Ozdarendeli A; Sezer Z; Pavel STI; Inal A; Yetiskin H; Kaplan B; Uygut MA; Bayram A; Mazicioglu M; Unuvar GK; Yuce ZT; Aydin G; Aslan AF; Kaya RK; Koc RC; Ates I; Kara A
    Vaccine; 2023 Jan; 41(2):380-390. PubMed ID: 36460536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.
    Kozlovskaya LI; Piniaeva AN; Ignatyev GM; Gordeychuk IV; Volok VP; Rogova YV; Shishova AA; Kovpak AA; Ivin YY; Antonova LP; Mefyod KM; Prokosheva LS; Sibirkina AS; Tarasova YY; Bayurova EO; Gancharova OS; Illarionova VV; Glukhov GS; Sokolova OS; Shaitan KV; Moysenovich AM; Gulyaev SA; Gulyaeva TV; Moroz AV; Gmyl LV; Ipatova EG; Kirpichnikov MP; Egorov AM; Siniugina AA; Ishmukhametov AA
    Emerg Microbes Infect; 2021 Dec; 10(1):1790-1806. PubMed ID: 34427172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.
    Martell BA; Orson FM; Poling J; Mitchell E; Rossen RD; Gardner T; Kosten TR
    Arch Gen Psychiatry; 2009 Oct; 66(10):1116-23. PubMed ID: 19805702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines' immunogenicity.
    Scendoni R; Bury E; Ribeiro ILA; Cameriere R; Cingolani M
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140552. PubMed ID: 36351881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human therapeutic cocaine vaccine: safety and immunogenicity.
    Kosten TR; Rosen M; Bond J; Settles M; Roberts JS; Shields J; Jack L; Fox B
    Vaccine; 2002 Jan; 20(7-8):1196-204. PubMed ID: 11803082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.
    Hicks MJ; De BP; Rosenberg JB; Davidson JT; Moreno AY; Janda KD; Wee S; Koob GF; Hackett NR; Kaminsky SM; Worgall S; Toth M; Mezey JG; Crystal RG
    Mol Ther; 2011 Mar; 19(3):612-9. PubMed ID: 21206484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a therapeutic vaccine for the treatment of cocaine addiction.
    Fox BS
    Drug Alcohol Depend; 1997 Dec; 48(3):153-8. PubMed ID: 9449013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of Abhay M and M-vac vaccines in healthy infants: a phase III multicentric randomized single blind trial.
    Zodpey SP; Agarkhedkar SR; Reddy GA; Rao MI; Shenoy UV; Murthy SR; Maiya PP
    Indian J Public Health; 2008; 52(1):5-10. PubMed ID: 18700714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates.
    Tukhvatulin AI; Gordeychuk IV; Dolzhikova IV; Dzharullaeva AS; Krasina ME; Bayurova EO; Grousova DM; Kovyrshina AV; Kondrashova AS; Avdoshina DV; Gulyaev SA; Gulyaeva TV; Moroz AV; Illarionova VV; Zorkov ID; Iliukhina AA; Shelkov AY; Botikov AG; Erokhova AS; Shcheblyakov DV; Esmagambetov IB; Zubkova OV; Tokarskaya EA; Savina DM; Vereveyko YR; Ungur AS; Naroditsky BS; Ishmukhametov AA; Logunov DY; Gintsburg AL
    Emerg Microbes Infect; 2022 Dec; 11(1):2229-2247. PubMed ID: 36031930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines against stimulants: cocaine and MA.
    Kosten T; Domingo C; Orson F; Kinsey B
    Br J Clin Pharmacol; 2014 Feb; 77(2):368-74. PubMed ID: 23509915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-cocaine vaccines: antibody protection against relapse.
    Kantak KM
    Expert Opin Pharmacother; 2003 Feb; 4(2):213-8. PubMed ID: 12562311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents.
    Ben-Yehuda A; Joseph A; Barenholz Y; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Galprin I; Glück R; Zurbriggen R; Kedar E
    Vaccine; 2003 Jul; 21(23):3169-78. PubMed ID: 12804845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GNE-KLH anti-cocaine vaccine protects dams and offspring from cocaine-induced effects during the prenatal and lactating periods.
    de Almeida Augusto PS; Pereira RLG; Caligiorne SM; Sabato B; Assis BRD; do Espírito Santo LP; Dos Reis KD; Castro Goulart GA; de Fátima Â; de Castro Lourenço das Neves M; Garcia FD
    Mol Psychiatry; 2021 Dec; 26(12):7784-7791. PubMed ID: 34381172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.